NYSE · PHARMACEUTICAL PREPARATIONS · LARGE CAP
Arcus Biosciences, Inc. RCUS
10 fiscal years on record · USD · FY2025 reported
SEC FILINGS ONLY
Revenue · FY2025
$33.0M
▼ 35.3% vs FY2024
EPS · FY25
$-3.29
Dividend / sh · FY25
—
Payout · FY25
—
ROE · FY25
-63.3%
Net margin · FY25
-1069.7%
Dividend coverage
—
Advertisement
AdSense · Leaderboard 728×90320×100
Result
USD 33.0M
Revenue, FY2025 · full 10-year series below
Revenue
Net income
The company lost 1070 cents on every revenue dollar this year.
Per share
USD -3.29
Diluted EPS, FY2025
EPS
The company pays no cash dividend.
Profitability
-63.3%
Return on equity, FY2025
ROE
Operating margin-1169.7%
Net margin-1069.7%
Return on assets-30.8%
Each USD of equity lost 63 cents this year.
Returned to shareholders
—
returned in FY2025 · dividends + net buybacks
Dividends paid—
Net buybacks—
Share of profit—
Consecutive raises—
Growth
−15.8% a year
revenue, compounded over five years
CAGR
3 yrs
5 yrs
10 yrs
15 yrs
Revenue
−4.6%
−15.8%
Compound annual rates per period — left blank where the series crosses a loss.
Share base
0.13B
Shares outstanding, FY2025
Change, 5 years+92.4%
Change, 10 years—
The share count grew 92% in five years — the same company, cut into more, smaller slices.
Advertisement
AdSense · Leaderboard 728×90300×250
Balance sheet
USD 1.1B
total assets, end of FY2025
Total assetsUSD 1.1B
EquityUSD 631.0M
CashUSD 222.0M
Gross debtUSD 99.0M
Net debtUSD -123.0M
Current ratio4.36×
The company holds more cash than debt.
History
10 fiscal years
Every figure from documents filed with the SEC · USD
Metric
2025
2024
2023
2022
2021
2020
2019
2018
2017
2016
Revenue $B
0.0
0.1
0.0
0.0
0.4
0.1
0.0
0.0
0.0
·
Operating income $B
−0.4
−0.3
−0.3
−0.3
0.1
−0.1
−0.1
−0.1
−0.1
−0.0
EBITDA $B
·
·
·
·
·
·
·
·
·
·
Income tax $B
0.0
0.0
0.0
0.0
0.0
·
·
·
·
·
Net income $B
−0.4
−0.3
−0.3
−0.3
0.1
−0.1
−0.1
−0.0
−0.1
−0.0
EPS, diluted $
−3.29
−3.14
−4.15
−3.71
0.71
−2.24
−1.93
−1.43
−29.03
−20.80
Dividend / sh $
·
·
·
·
·
·
·
·
·
·
Payout %
·
·
·
·
·
·
·
·
·
·
ROE %
−63.3
−59.8
−54.9
−35.6
7.9
−36.9
−42.5
−61.0
·
·
Shares out B
0.13
0.09
0.08
0.07
0.07
0.07
0.05
0.04
0.00
·
Slide the table for earlier years · "·" marks figures not disclosed in the filing for that year.
How we verifyAUDITED
26 of 28
checks passed before publication
EPS recomputationBalance-sheet identityGross profitBalance-sheet liquidity
Every figure was compared against the original statement: 2 failures and 0 presentation gaps.
What we don’t show
We’d rather say what’s missing than fill the gap with an estimate.
P/E rationeeds a market quote — not yet licensed
Market capitalizationneeds a market quote — not yet licensed
Dividend yieldneeds a market quote — not yet licensed
Price-to-bookneeds a market quote — not yet licensed